First evidence of tick-borne encephalitis (TBE) outside of Hokkaido Island in Japan.

Autor:	Ohira M; Department of Clinical Laboratory and Internal Medicine, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan., Yoshii K; National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki City, Japan., Aso Y; Department of Neurology, Oita Prefectural Hospital, Oita, Japan., Nakajima H; Department of Neurology, Nihon University Itabashi Hospital, Tokyo, Japan., Yamashita T; Department of Neurology, Okayama University Hospital, Okayama, Japan., Takahashi-Iwata I; Department of Neurology, Hokkaido University Hospital, Hokkaido, Japan., Maeda N; Department of Neurology, National Hospital Organization Beppu Medical Center, Oita, Japan., Shindo K; Department or Neurology, Kurashiki Central Hospital, Okayama, Japan., Suenaga T; Department of Neurology, Tenri Hospital, Nara, Japan., Matsuura T; Division of Neurology, Jichi Medical University Hospital, Tochigi, Japan., Sugie K; Department of Neurology, Nara Medical University Hospital, Nara, Japan., Hamano T; Department of Neurology, University of Fukui Hospital, Fukui, Japan., Arai A; Aomori Prefectural Central Hospital, Aomori, Japan., Furutani R; Department of Neurology, National Hospital Organization Shinshu Ueda Medical Center, Nagano, Japan., Suzuki Y; Department of Neurology, National Hospital Organization Asahikawa Medical Center, Hokkaido, Japan., Kaneko C; Department of Neurology, Southern Tohoku General Hospital, Fukushima, Japan., Kobayashi Y; Vaccine Medical Affairs, Pfizer Japan Inc, Tokyo, Japan., Campos-Alberto E; Medical Affairs, CSL Behring, Tokyo, Japan., Harper LR; Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Collegeville, PA, USA., Edwards J; Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Collegeville, PA, USA., Bender C; Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Collegeville, PA, USA., Pilz A; Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Vienna, Austria., Ito S; Vaccine Medical Affairs, Pfizer Japan Inc, Tokyo, Japan., Angulo FJ; Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Collegeville, PA, USA., Erber W; Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Vienna, Austria., Madhava H; Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, London, UK., Moïsi J; Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Paris, France., Jodar L; Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Collegeville, PA, USA., Mizusawa H; Department of Neurology, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan., Takao M; Department of Clinical Laboratory and Internal Medicine, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Emerging microbes & infections [Emerg Microbes Infect] 2023 Dec; Vol. 12 (2), pp. 2278898. Date of Electronic Publication: 2023 Nov 14.
DOI:	10.1080/22221751.2023.2278898
Abstrakt:	Tick-borne encephalitis (TBE) is an infection of the central nervous system caused by the tick-borne encephalitis virus (TBEV). TBE is endemic in parts of Europe and Asia. TBEV is transmitted to humans primarily by Ixodes ticks. There have been 5 TBE cases identified in Japan, all on the northern island of Hokkaido. Rodents with TBEV antibodies and Ixodes ticks have been identified throughout Japan, indicating that TBEV infection might be undiagnosed in Japan. Residual serum and cerebrospinal fluid (CSF) collected in 2010-2021 from 520 patients ≥1 year-of-age previously hospitalized with encephalitis or meningitis of unknown etiology at 15 hospitals (including 13 hospitals outside of Hokkaido) were screened by ELISA for TBEV IgG and IgM antibodies; TBEV infection was confirmed by the gold standard neutralization test. Residual serum was available from 331 (63.6%) patients and CSF from 430 (82.6%) patients; both serum and CSF were available from 189 (36.3%). Two patients were TBE cases: a female aged 61 years hospitalized for 104 days in Oita (2000 km south of Hokkaido) and a male aged 24 years hospitalized for 11 days in Tokyo (1200 km south of Hokkaido). Retrospective testing also identified a previous TBEV infection in a female aged 45 years hospitalized for 12 days in Okayama (1700 km south of Hokkaido). TBEV infection should be considered as a potential cause of encephalitis or meningitis in Japan. TBE cases are likely undiagnosed in Japan, including outside of Hokkaido, due to limited clinical awareness and lack of availability of TBE diagnostic tests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu